SPHK1 and ovarian carcinoma: Previous studies have demonstrated that SPHK1 is associated with resistance to conventional chemotherapy, and recent evidence indicates that SPHK1 enhances Olaparib resistance in ovarian cancer via the NFκB/NRF2/ferroptosis pathway [15,49].